Compare D R Horton Inc (DHI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Zoetis Inc — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: D R Horton Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Zoetis Inc for 70 Days on average.
| DHI | ZTS | |
|---|---|---|
Market Cap | $37.99B | $30.20B |
Volume | 2,974,460 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $147.53 |
52-Week Low | $132.53 | $69.09 |
Typical Hold Time | 46 Days | 70 Days |
Enterprise Value | $43.09B | $37.76B |
Dividend Yield | 1.33% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $135.82, up 1.91% today, but faces a bearish technical outlook with resistance at $137. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue declined to $34.25B in 2025, and net income margin compressed to 9.15%. Analysts maintain a buy consensus with a $156.57 target, but rising mortgage rates and housing market weakness pose headwinds.
The stock offers value with a P/E of 12.95 and strong cash flow, but investor sentiment is cautious due to macroeconomic risks. Near-term performance hinges on Q3 earnings and interest rate trends. The current price near the low end of the target range suggests limited downside if fundamentals hold.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
